The European Commission already has preliminary agreements to purchase 1,105 million doses of five different experimental vaccines against covid: 300 million the Oxford candidate (who just stopped her rehearsals this Thursday); another 300 million from that developed by the French multinational Sanofi and the British GSK; 225 million for the prototype of the German biotechnology company Curevac; 200 million from the option of the American company Johnson & Johnson, and 80 million doses from the also American company Moderna. All of these experimental vaccines have offered encouraging results to date, but none have yet been proven to work.
